Annual report
4671.TEDINET S100OCZP
Period2021-04-01 → 2022-03-31
Filed2022-06-22
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 158
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥50.0bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales |
| Revenue | ¥43.6bn | 2020-04-01 → 2021-03-31 | Cons. | Net sales |
| Revenue | ¥43.2bn | 2019-04-01 → 2020-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥44.2bn | 2018-04-01 → 2019-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥46.0bn | 2017-04-01 → 2018-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥5.5bn | 2021-04-01 → 2022-03-31 | Cons. | Operating income |
| Operating income | ¥2.6bn | 2020-04-01 → 2021-03-31 | Cons. | Operating income |
| Ordinary income | ¥5.8bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥2.9bn | 2020-04-01 → 2021-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥941m | 2019-04-01 → 2020-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.6bn | 2018-04-01 → 2019-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥2.4bn | 2017-04-01 → 2018-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥5.6bn | 2021-04-01 → 2022-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥2.9bn | 2020-04-01 → 2021-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥3.5bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥1.9bn | 2020-04-01 → 2021-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥1.2bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥653m | 2018-04-01 → 2019-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥1.7bn | 2017-04-01 → 2018-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥3.5bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss |
| Net income | ¥1.9bn | 2020-04-01 → 2021-03-31 | Cons. | Profit loss |
| Total assets | ¥40.3bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥37.1bn | at 2021-03-31 | Cons. | Assets |
| Total assets | ¥32.0bn | at 2020-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥32.1bn | at 2019-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥32.7bn | at 2018-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥16.8bn | at 2022-03-31 | Cons. | Liabilities |
| Total liabilities | ¥16.6bn | at 2021-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥23.5bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥20.5bn | at 2021-03-31 | Cons. | Net assets |
| Net assets / equity | ¥18.9bn | at 2020-03-31d | Cons. | Net assets |
| Net assets / equity | ¥19.0bn | at 2019-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥19.1bn | at 2018-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥10.6bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥11.6bn | at 2021-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥10.6bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥11.6bn | at 2021-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥7.3bn | at 2020-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥7.8bn | at 2019-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥8.4bn | at 2018-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥4.1bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥2.9bn | 2020-04-01 → 2021-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.9bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.7bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥2.3bn | 2017-04-01 → 2018-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥2.7bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥52m | 2020-04-01 → 2021-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.2bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥1.3bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥615m | 2017-04-01 → 2018-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥2.4bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥1.5bn | 2020-04-01 → 2021-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥1.3bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥845m | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥41m | 2017-04-01 → 2018-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥339 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥178.61 | 2020-04-01 → 2021-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥116.87 | 2019-04-01 → 2020-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥59.8 | 2018-04-01 → 2019-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥156.12 | 2017-04-01 → 2018-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥336.99 | 2021-04-01 → 2022-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥177.54 | 2020-04-01 → 2021-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥116.06 | 2019-04-01 → 2020-03-31d | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥59.44 | 2018-04-01 → 2019-03-31d | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥155.65 | 2017-04-01 → 2018-03-31d | Cons. | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥2,237.14 | at 2022-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,966.43 | at 2021-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,776.01 | at 2020-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,725.03 | at 2019-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,745.4 | at 2018-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 58.1% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 55.0% | at 2021-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 58.8% | at 2020-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 58.9% | at 2019-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 58.2% | at 2018-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 16.1% | 2021-04-01 → 2022-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 9.5% | 2020-04-01 → 2021-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 6.6% | 2019-04-01 → 2020-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 3.5% | 2018-04-01 → 2019-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 9.3% | 2017-04-01 → 2018-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 1,179 | at 2022-03-31 | Cons. | Number of employees |
| Employees | 1,200 | at 2021-03-31 | Cons. | Number of employees |
| Employees | 1,249 | at 2020-03-31d | Cons. | Number of employees |
| Employees | 1,348 | at 2019-03-31d | Cons. | Number of employees |
| Employees | 1,377 | at 2018-03-31d | Cons. | Number of employees |
| Revenue | ¥3.8bn | 2021-04-01 → 2022-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥1.9bn | 2020-04-01 → 2021-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥2.4bn | 2019-04-01 → 2020-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥4.1bn | 2018-04-01 → 2019-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥2.0bn | 2017-04-01 → 2018-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Operating income | ¥2.7bn | 2021-04-01 → 2022-03-31 | Standalone | Operating income |
| Operating income | ¥722m | 2020-04-01 → 2021-03-31 | Standalone | Operating income |
| Ordinary income | ¥2.8bn | 2021-04-01 → 2022-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥806m | 2020-04-01 → 2021-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥1.2bn | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥3.1bn | 2018-04-01 → 2019-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥742m | 2017-04-01 → 2018-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥2.6bn | 2021-04-01 → 2022-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥1.0bn | 2020-04-01 → 2021-03-31 | Standalone | Income before income taxes |
| Net income | ¥2.6bn | 2021-04-01 → 2022-03-31 | Standalone | Profit loss |
| Net income | ¥1.0bn | 2020-04-01 → 2021-03-31 | Standalone | Profit loss |
| Net income | ¥1.3bn | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥3.1bn | 2018-04-01 → 2019-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥990m | 2017-04-01 → 2018-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥24.3bn | at 2022-03-31 | Standalone | Assets |
| Total assets | ¥24.2bn | at 2021-03-31 | Standalone | Assets |
| Total assets | ¥20.7bn | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥21.6bn | at 2019-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥21.3bn | at 2018-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥4.2bn | at 2022-03-31 | Standalone | Liabilities |
| Total liabilities | ¥6.2bn | at 2021-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥20.1bn | at 2022-03-31 | Standalone | Net assets |
| Net assets / equity | ¥18.0bn | at 2021-03-31 | Standalone | Net assets |
| Net assets / equity | ¥17.3bn | at 2020-03-31d | Standalone | Net assets |
| Net assets / equity | ¥17.4bn | at 2019-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥15.0bn | at 2018-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥8.2bn | at 2022-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥9.7bn | at 2021-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥254.07 | 2021-04-01 → 2022-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥96.55 | 2020-04-01 → 2021-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥118.11 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥281.59 | 2018-04-01 → 2019-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥91.1 | 2017-04-01 → 2018-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥252.56 | 2021-04-01 → 2022-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥95.97 | 2020-04-01 → 2021-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥117.29 | 2019-04-01 → 2020-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥279.93 | 2018-04-01 → 2019-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥90.82 | 2017-04-01 → 2018-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥64 | 2021-04-01 → 2022-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥54 | 2020-04-01 → 2021-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥48 | 2019-04-01 → 2020-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥46 | 2018-04-01 → 2019-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥44 | 2017-04-01 → 2018-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥1,914.28 | at 2022-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,726.33 | at 2021-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,621.07 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,574.26 | at 2019-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,371.3 | at 2018-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 82.4% | at 2022-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 73.9% | at 2021-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 83.1% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 80.1% | at 2019-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 70.0% | at 2018-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 14.0% | 2021-04-01 → 2022-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 5.7% | 2020-04-01 → 2021-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 7.3% | 2019-04-01 → 2020-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 19.1% | 2018-04-01 → 2019-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.8% | 2017-04-01 → 2018-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 11,280,177 | at 2022-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 11,280,177 | at 2021-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 11,280,177 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 11,280,177 | at 2019-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 11,280,177 | at 2018-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 3 | at 2022-03-31 | Standalone | Number of employees |
| Employees | 2 | at 2021-03-31 | Standalone | Number of employees |
| Employees | 2 | at 2020-03-31d | Standalone | Number of employees |
| Employees | 4 | at 2019-03-31d | Standalone | Number of employees |
| Employees | 5 | at 2018-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 56
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2021-04-01 → 2022-03-31 | ¥1.7bn |
| Reconciling Itemsreconciling | depreciation | 2021-04-01 → 2022-03-31 | ¥198m |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2022-03-31 | −¥16m |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2022-03-31 | −¥16m |
| Reconciling Itemsreconciling | segment assets | at 2022-03-31 | ¥21.5bn |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2022-03-31 | −¥403m |
| Clinical Testing Businessreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥580m |
| Clinical Testing Businessreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥628m |
| Clinical Testing Businessreportable segment | employees | at 2022-03-31 | 762 pure |
| Clinical Testing Businessreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥33.7bn |
| Clinical Testing Businessreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥33.7bn |
| Clinical Testing Businessreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥15m |
| Clinical Testing Businessreportable segment | segment assets | at 2022-03-31 | ¥13.1bn |
| Clinical Testing Businessreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥4.9bn |
| Dispensing Pharmacy Businessreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥204m |
| Dispensing Pharmacy Businessreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥115m |
| Dispensing Pharmacy Businessreportable segment | employees | at 2022-03-31 | 393 pure |
| Dispensing Pharmacy Businessreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥16.4bn |
| Dispensing Pharmacy Businessreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥16.4bn |
| Dispensing Pharmacy Businessreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥1m |
| Dispensing Pharmacy Businessreportable segment | segment assets | at 2022-03-31 | ¥5.6bn |
| Dispensing Pharmacy Businessreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥1.0bn |
| —segment total | capex | 2021-04-01 → 2022-03-31 | ¥784m |
| —segment total | depreciation | 2021-04-01 → 2022-03-31 | ¥744m |
| —segment total | revenue | 2021-04-01 → 2022-03-31 | ¥50.0bn |
| —segment total | revenue external | 2021-04-01 → 2022-03-31 | ¥50.0bn |
| —segment total | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥16m |
| —segment total | segment assets | at 2022-03-31 | ¥18.7bn |
| —segment total | segment profit | 2021-04-01 → 2022-03-31 | ¥5.9bn |
| Reconciling Itemsreconciling | capex | 2020-04-01 → 2021-03-31 | ¥1.2bn |
| Reconciling Itemsreconciling | depreciation | 2020-04-01 → 2021-03-31 | ¥184m |
| Reconciling Itemsreconciling | revenue | 2020-04-01 → 2021-03-31 | −¥16m |
| Reconciling Itemsreconciling | revenue intersegment | 2020-04-01 → 2021-03-31 | −¥16m |
| Reconciling Itemsreconciling | segment assets | at 2021-03-31 | ¥20.9bn |
| Reconciling Itemsreconciling | segment profit | 2020-04-01 → 2021-03-31 | −¥328m |
| Clinical Testing Businessreportable segment | capex | 2020-04-01 → 2021-03-31 | ¥310m |
| Clinical Testing Businessreportable segment | depreciation | 2020-04-01 → 2021-03-31 | ¥630m |
| Clinical Testing Businessreportable segment | revenue | 2020-04-01 → 2021-03-31 | ¥27.2bn |
| Clinical Testing Businessreportable segment | revenue external | 2020-04-01 → 2021-03-31 | ¥27.2bn |
| Clinical Testing Businessreportable segment | revenue intersegment | 2020-04-01 → 2021-03-31 | ¥15m |
| Clinical Testing Businessreportable segment | segment assets | at 2021-03-31 | ¥11.0bn |
| Clinical Testing Businessreportable segment | segment profit | 2020-04-01 → 2021-03-31 | ¥2.0bn |
| Dispensing Pharmacy Businessreportable segment | capex | 2020-04-01 → 2021-03-31 | ¥30m |
| Dispensing Pharmacy Businessreportable segment | depreciation | 2020-04-01 → 2021-03-31 | ¥121m |
| Dispensing Pharmacy Businessreportable segment | revenue | 2020-04-01 → 2021-03-31 | ¥16.4bn |
| Dispensing Pharmacy Businessreportable segment | revenue external | 2020-04-01 → 2021-03-31 | ¥16.4bn |
| Dispensing Pharmacy Businessreportable segment | revenue intersegment | 2020-04-01 → 2021-03-31 | ¥1m |
| Dispensing Pharmacy Businessreportable segment | segment assets | at 2021-03-31 | ¥5.2bn |
| Dispensing Pharmacy Businessreportable segment | segment profit | 2020-04-01 → 2021-03-31 | ¥968m |
| —segment total | capex | 2020-04-01 → 2021-03-31 | ¥341m |
| —segment total | depreciation | 2020-04-01 → 2021-03-31 | ¥752m |
| —segment total | revenue | 2020-04-01 → 2021-03-31 | ¥43.6bn |
| —segment total | revenue external | 2020-04-01 → 2021-03-31 | ¥43.6bn |
| —segment total | revenue intersegment | 2020-04-01 → 2021-03-31 | ¥16m |
| —segment total | segment assets | at 2021-03-31 | ¥16.2bn |
| —segment total | segment profit | 2020-04-01 → 2021-03-31 | ¥2.9bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,546
| Item | Context | Value | Unit |
|---|---|---|---|
| Revenues from external customers | CurrentYearDuration_ReportableSegmentsMember | 50007000000 | JPY |
| Revenues from external customers | CurrentYearDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | CurrentYearDuration | 50007000000 | JPY |
| Transactions with other segments | CurrentYearDuration_jpcrp030000-asr_E04982-000ClinicalTestingBusinessReportableSegmentsMember | 15000000 | JPY |
| Transactions with other segments | CurrentYearDuration_jpcrp030000-asr_E04982-000DispensingPharmacyBusinessReportableSegmentsMember | 1000000 | JPY |
| Transactions with other segments | CurrentYearDuration_ReportableSegmentsMember | 16000000 | JPY |
| Transactions with other segments | CurrentYearDuration_ReconcilingItemsMember | -16000000 | JPY |
| Transactions with other segments | CurrentYearDuration | － | JPY |
| Net sales | CurrentYearDuration_jpcrp030000-asr_E04982-000ClinicalTestingBusinessReportableSegmentsMember | 33670000000 | JPY |
| Net sales | CurrentYearDuration_jpcrp030000-asr_E04982-000DispensingPharmacyBusinessReportableSegmentsMember | 16353000000 | JPY |
| Net sales | CurrentYearDuration_ReportableSegmentsMember | 50024000000 | JPY |
| Net sales | CurrentYearDuration_ReconcilingItemsMember | -16000000 | JPY |
| Net sales | CurrentYearDuration | 50007000000 | JPY |
| Operating income | CurrentYearDuration_jpcrp030000-asr_E04982-000ClinicalTestingBusinessReportableSegmentsMember | 4894000000 | JPY |
| Operating income | CurrentYearDuration_jpcrp030000-asr_E04982-000DispensingPharmacyBusinessReportableSegmentsMember | 1005000000 | JPY |
| Operating income | CurrentYearDuration_ReportableSegmentsMember | 5899000000 | JPY |
| Operating income | CurrentYearDuration_ReconcilingItemsMember | -403000000 | JPY |
| Operating income | CurrentYearDuration | 5496000000 | JPY |
| Assets | CurrentYearInstant_jpcrp030000-asr_E04982-000ClinicalTestingBusinessReportableSegmentsMember | 13114000000 | JPY |
| Assets | CurrentYearInstant_jpcrp030000-asr_E04982-000DispensingPharmacyBusinessReportableSegmentsMember | 5617000000 | JPY |
| Assets | CurrentYearInstant_ReportableSegmentsMember | 18731000000 | JPY |
| Assets | CurrentYearInstant_ReconcilingItemsMember | 21525000000 | JPY |
| Assets | CurrentYearInstant | 40256000000 | JPY |
| Depreciation segment information | CurrentYearDuration_jpcrp030000-asr_E04982-000ClinicalTestingBusinessReportableSegmentsMember | 628000000 | JPY |
| Depreciation segment information | CurrentYearDuration_jpcrp030000-asr_E04982-000DispensingPharmacyBusinessReportableSegmentsMember | 115000000 | JPY |
| Depreciation segment information | CurrentYearDuration_ReportableSegmentsMember | 744000000 | JPY |
| Depreciation segment information | CurrentYearDuration_ReconcilingItemsMember | 198000000 | JPY |
| Depreciation segment information | CurrentYearDuration | 942000000 | JPY |
| Amortization of goodwill sga | CurrentYearDuration_jpcrp030000-asr_E04982-000ClinicalTestingBusinessReportableSegmentsMember | 14000000 | JPY |
| Amortization of goodwill sga | CurrentYearDuration_jpcrp030000-asr_E04982-000DispensingPharmacyBusinessReportableSegmentsMember | 2000000 | JPY |
| Amortization of goodwill sga | CurrentYearDuration_ReportableSegmentsMember | 16000000 | JPY |
| Amortization of goodwill sga | CurrentYearDuration_ReconcilingItemsMember | － | JPY |
| Amortization of goodwill sga | CurrentYearDuration | 16000000 | JPY |
| Impairment loss el | CurrentYearDuration_jpcrp030000-asr_E04982-000ClinicalTestingBusinessReportableSegmentsMember | 0 | JPY |
| Impairment loss el | CurrentYearDuration_jpcrp030000-asr_E04982-000DispensingPharmacyBusinessReportableSegmentsMember | 35000000 | JPY |
| Impairment loss el | CurrentYearDuration_ReportableSegmentsMember | 35000000 | JPY |
| Impairment loss el | CurrentYearDuration_ReconcilingItemsMember | 137000000 | JPY |
| Impairment loss el | CurrentYearDuration | 173000000 | JPY |
| Increase in property plant and equipment and intangible assets | CurrentYearDuration_jpcrp030000-asr_E04982-000ClinicalTestingBusinessReportableSegmentsMember | 580000000 | JPY |
| Increase in property plant and equipment and intangible assets | CurrentYearDuration_jpcrp030000-asr_E04982-000DispensingPharmacyBusinessReportableSegmentsMember | 204000000 | JPY |
| Increase in property plant and equipment and intangible assets | CurrentYearDuration_ReportableSegmentsMember | 784000000 | JPY |
| Increase in property plant and equipment and intangible assets | CurrentYearDuration_ReconcilingItemsMember | 1723000000 | JPY |
| Increase in property plant and equipment and intangible assets | CurrentYearDuration | 2508000000 | JPY |
| Goodwill | Prior1YearInstant_jpcrp030000-asr_E04982-000ClinicalTestingBusinessReportableSegmentsMember | 38000000 | JPY |
| Goodwill | Prior1YearInstant_jpcrp030000-asr_E04982-000DispensingPharmacyBusinessReportableSegmentsMember | 6000000 | JPY |
| Goodwill | Prior1YearInstant_UnallocatedAmountsAndEliminationMember | － | JPY |
| Goodwill | Prior1YearInstant | 45000000 | JPY |
| Goodwill | CurrentYearInstant_jpcrp030000-asr_E04982-000ClinicalTestingBusinessReportableSegmentsMember | 24000000 | JPY |
| Goodwill | CurrentYearInstant_jpcrp030000-asr_E04982-000DispensingPharmacyBusinessReportableSegmentsMember | 4000000 | JPY |
| Goodwill | CurrentYearInstant_UnallocatedAmountsAndEliminationMember | － | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |